Drug Profile
Turofexorate isopropyl
Alternative Names: 6m; FXR-450; WAY-362450; XL335Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Exelixis
- Developer Pfizer
- Class Antihyperlipidaemics; Azepines; Esters; Indoles; Small molecules
- Mechanism of Action Farnesoid X-activated receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Atherosclerosis; Hyperlipidaemia; Non-alcoholic steatohepatitis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Hyperlipidaemia(In volunteers) in Japan (PO, Capsule)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Hyperlipidaemia(In volunteers) in USA (PO, Capsule)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Atherosclerosis in USA (PO, Capsule)